These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 26905101)
1. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors. Thangaraju P; Singh H; Chakrabarti A Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101 [TBL] [Abstract][Full Text] [Related]
2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. Crona DJ; Keisler MD; Walko CM Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629 [TBL] [Abstract][Full Text] [Related]
3. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Rutkowski P; Stępniak J Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387 [TBL] [Abstract][Full Text] [Related]
4. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours. Shirley M; Keating GM Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375 [TBL] [Abstract][Full Text] [Related]
5. Regorafenib: carving a niche in the crowded therapeutic landscape. Sirohi B; Philip DS; Shrikhande SV Expert Rev Anticancer Ther; 2013 Apr; 13(4):385-93. PubMed ID: 23560833 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941 [TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Mohammadi M; Gelderblom H Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274 [No Abstract] [Full Text] [Related]
8. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967 [TBL] [Abstract][Full Text] [Related]
9. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib. Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770 [TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Le Tourneau C; Raymond E; Faivre S Ther Clin Risk Manag; 2007 Jun; 3(2):341-8. PubMed ID: 18360643 [TBL] [Abstract][Full Text] [Related]
13. The development of regorafenib and its current and potential future role in cancer therapy. Davis SL; Eckhardt SG; Messersmith WA; Jimeno A Drugs Today (Barc); 2013 Feb; 49(2):105-15. PubMed ID: 23462625 [TBL] [Abstract][Full Text] [Related]
14. Regorafenib. Ettrich TJ; Seufferlein T Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792 [TBL] [Abstract][Full Text] [Related]
15. Regorafenib for treatment of advanced gastrointestinal stromal tumors. Overton LC; Heinrich MC Expert Opin Pharmacother; 2014 Mar; 15(4):549-58. PubMed ID: 24405315 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis. Zhang Z; Jiang T; Wang W; Piao D Medicine (Baltimore); 2017 Dec; 96(48):e8698. PubMed ID: 29310342 [TBL] [Abstract][Full Text] [Related]
17. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. Aprile G; Macerelli M; Giuliani F BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872 [TBL] [Abstract][Full Text] [Related]
18. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer]. Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib]. Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328 [TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. Papadimitriou M; Papadimitriou CA Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]